

8th International Conference on

Clinical Gastroenterology & Hepatology

October 03-05, 2016 Toronto, Canada



Indran Indrakrishnan

Clinical Professor of Medicine, USA

Update on proton Pump Inhibitors

Proton pump inhibitors (PPIs) are one of the most commonly prescribed classes of medications and are bought by the public over the counter very frequently. Proton pump inhibitors were introduced in 1980's and they have demonstrated gastric acid suppression superior to that of previous block buster drug histamine H₂-receptor blockers. The first proton pump inhibitor was Omeprazole, and later Lansoprazole and Rabeprazole were introduced. Esomeprazole and Dexlansaprazole came in to the market in the last decade as purified Isomers. Proton pump inhibitors have enabled improved treatment of various acid-peptic disorders, including GERD, peptic ulcer disease, and NSAID drug-induced gastropathy. In the first two decades, proton pump inhibitors were thought to have minimal side effects and few significant drug interactions, and they were generally considered safe for long-term treatment. However, the landscape has changed lately and current knowledge of the proton pump inhibitors will be discussed.

Biography

Indran Indrakrishnan is a Clinical Professor of Medicine at the Emory University School of Medicine and the Medical Director of GDC Endoscopy Center LLC & Gwinnett Digestive Clinic PC in Atlanta GA. He was the Former President and currently on the Board of Directors of Georgia Gastroenterological and Endoscopic Society. He has served and has been serving on numerous committees including American College of Gastroenterology, American College of Physicians, Medical Association of Georgia and AAAHC International. He has organized and spoken at many CME conferences across the country and has won many distinguished awards from national and international scientific organizations. He has published several Clinical and Basic Science research articles and is in the Editorial Boards of peer review journals. He has a special interest in the Management and Public Education of Colorectal Cancer and is on the Board of Directors of Fight Colorectal Cancer, a national non-profit patient advocacy organization.

bindrak@emory.edu